These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9258386)

  • 1. Interaction of genetic and exposure factors in the prevalence of berylliosis.
    Richeldi L; Kreiss K; Mroz MM; Zhen B; Tartoni P; Saltini C
    Am J Ind Med; 1997 Oct; 32(4):337-40. PubMed ID: 9258386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69.
    Amicosante M; Berretta F; Rossman M; Butler RH; Rogliani P; van den Berg-Loonen E; Saltini C
    Respir Res; 2005 Aug; 6(1):94. PubMed ID: 16098233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major histocompatibility locus genetic markers of beryllium sensitization and disease.
    Saltini C; Richeldi L; Losi M; Amicosante M; Voorter C; van den Berg-Loonen E; Dweik RA; Wiedemann HP; Deubner DC; Tinelli C
    Eur Respir J; 2001 Oct; 18(4):677-84. PubMed ID: 11716174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.
    Richeldi L; Sorrentino R; Saltini C
    Science; 1993 Oct; 262(5131):242-4. PubMed ID: 8105536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the HLA-DP Glu 69 and the TNF-alpha TNF-alpha 2 gene markers in susceptibility to beryllium hypersensitivity.
    Rogliani P; Amicosante M; Berretta F; Dotti C; Bocchino M; O'Donnell KM; Saltini C
    Int J Immunopathol Pharmacol; 2004; 17(2 Suppl):3-10. PubMed ID: 15345185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells.
    Amicosante M; Berretta F; Franchi A; Rogliani P; Dotti C; Losi M; Dweik R; Saltini C
    Eur Respir J; 2002 Nov; 20(5):1174-8. PubMed ID: 12449171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and environmental risk factors in beryllium sensitization and chronic beryllium disease.
    Maier L; Martyny J; Mroz M; McGrath D; Lympany P; duBois R; Zhang L; Murphy J; Newman LS
    Chest; 2002 Mar; 121(3 Suppl):81S. PubMed ID: 11893702
    [No Abstract]   [Full Text] [Related]  

  • 8. Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease.
    Weston A; Ensey J; Kreiss K; Keshava C; McCanlies E
    Am J Ind Med; 2002 Jun; 41(6):457-65. PubMed ID: 12173370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To Be2+ or not to Be2+: immunogenetics and occupational exposure.
    Newman LS
    Science; 1993 Oct; 262(5131):197-8. PubMed ID: 8105535
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease.
    Maier LA; McGrath DS; Sato H; Lympany P; Welsh K; Du Bois R; Silveira L; Fontenot AP; Sawyer RT; Wilcox E; Newman LS
    J Immunol; 2003 Dec; 171(12):6910-8. PubMed ID: 14662898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the berylliosis-associated HLA-DPGlu69 supratypic variant in determining the response to beryllium in a blood T-cells beryllium-stimulated proliferation test.
    Amicosante M; Deubner D; Saltini C
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Oct; 22(3):175-9. PubMed ID: 16315779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genetic marker for chronic beryllium disease.
    Saltini C; Richeldi L
    Med Lav; 1995; 86(3):226-8. PubMed ID: 7565282
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunogenetic basis of environmental lung disease: lessons from the berylliosis model.
    Saltini C; Amicosante M; Franchi A; Lombardi G; Richeldi L
    Eur Respir J; 1998 Dec; 12(6):1463-75. PubMed ID: 9877510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linking genetic susceptibility and T cell activation in beryllium-induced disease.
    Falta MT; Bowerman NA; Dai S; Kappler JW; Fontenot AP
    Proc Am Thorac Soc; 2010 May; 7(2):126-9. PubMed ID: 20427584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-DPB1 and chronic beryllium disease: a HuGE review.
    McCanlies EC; Kreiss K; Andrew M; Weston A
    Am J Epidemiol; 2003 Mar; 157(5):388-98. PubMed ID: 12615603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers.
    Van Dyke MV; Martyny JW; Mroz MM; Silveira LJ; Strand M; Fingerlin TE; Sato H; Newman LS; Maier LA
    Am J Respir Crit Care Med; 2011 Jun; 183(12):1680-8. PubMed ID: 21471109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.
    Fontenot AP; Torres M; Marshall WH; Newman LS; Kotzin BL
    Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12717-22. PubMed ID: 11050177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain.
    Bill JR; Mack DG; Falta MT; Maier LA; Sullivan AK; Joslin FG; Martin AK; Freed BM; Kotzin BL; Fontenot AP
    J Immunol; 2005 Nov; 175(10):7029-37. PubMed ID: 16272364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization.
    McCanlies EC; Ensey JS; Schuler CR; Kreiss K; Weston A
    Am J Ind Med; 2004 Aug; 46(2):95-103. PubMed ID: 15273960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beryllium disease.
    Saltini C; Amicosante M
    Am J Med Sci; 2001 Jan; 321(1):89-98. PubMed ID: 11202485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.